Gefitinib in cervical cancer

A Prospective randomized open label study to evaluate the response rate and toxicity of Gefitinib in the treatment of carcinoma cervix patients on chemoradiotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/12/010726

Enrollment

Registered

2017-12-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Cervical cancer stage II to III

Interventions

Intervention1: Tablet Gefitinib 250 mg given orally daily through out the course of external radiation.: concurrent chemoradiation. The dose of radiation is 50Gy/25 fraction, along with cisplatin of 4

Eligibility

Inclusion criteria

Inclusion criteria: 1. FIGO stage II to III cervical cancer. 2. Histopathologically proven cervical cancer. 3. Serum creatinine

Exclusion criteria

Exclusion criteria: 1. Pregnant and breast feeding patients. 2. Immunocompromised patients and with Human immunodeficient virsu (HIV) infection. 3. Any allergy to Cisplatin and Gefitinib. 4. Prior surgery for cervical cancer.

Design outcomes

Primary

Measure	Time frame
To evaluate the response rate with the addition of Gefitinib in cervical cancer patients receiving chemoradiation.Timepoint: at the end of 6 months	—

Secondary

Measure	Time frame
To evaluate the toxicity during the treatmentTimepoint: during the treatment and post treatment at 6 months	—

Countries

India

Contacts

Public ContactDr Mukesh S

Mysore medical college and research institute

dal_muk1@hotmail.com919886873788

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026